Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00055133
Status:
COMPLETED
Last Update Posted:
2008-07-29
First Post:
2003-02-19
Brief Title:
A Study Using Intravenous Paxceed to Treat Patients With Rheumatoid Arthritis
Sponsor:
Angiotech Pharmaceuticals
Organization:
Angiotech Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Open-Label Clinical Study Using Intravenous Paxceed to Treat Patients With Rheumatoid Arthritis
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Paxceed is being developed by Angiotech Pharmaceuticals Inc for the treatment of Rheumatoid Arthritis RA The main objective of this study is to determine the effectiveness of treatment with Paxceed in patients with RA In RA there is an increase in cell growth and changes in cell function The active substance in Paxceed paclitaxel has undergone clinical studies as a cancer chemotherapeutic agent and has demonstrated its usefulness as an agent that stops growth of cells and blocks certain types of cell function associated with RA Because of these effects it is thought that Paxceed might alter the destructive course of RA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None